Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05315479 · ClinicalTrials.gov registry record · Phase 4
Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery
A Phase 4 study, sponsored by Baudax Bio.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT05315479 is a Phase 4 study that was terminated before completion, run by Baudax Bio. The registered enrollment target is 19 participants.
The verdict
NCT05315479, a Phase 4 study, was terminated before completion, sponsored by Baudax Bio.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to \<17 years.
Interventions
- DRUG N1539
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05315479
The ClinicalTrials.gov registry entry for NCT05315479 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baudax Bio, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N1539 is the first listed.
NCT05315479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05315479 about?
NCT05315479 is a clinical study titled "Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery". This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to \<17 years.
What is the current status of trial NCT05315479?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2022-02-24. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT05315479?
The interventions under investigation include: N1539 (DRUG).
Who is sponsoring clinical trial NCT05315479?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.